Cancer Pain Management Market Overview
The global Cancer Pain Management market is expected to rise at a significant rate in the forecast period. Approximately 70.0% of cancer patients could suffer from chronic pain because of spinal cord injuries, 28.0% due to multiple sclerosis, and 8.0% due to stroke. In addition, 75.0% of the patients are projected to complain of a gradual rise in pain with the progression of the disease. Therefore, a growing number of patients experiencing such pain will be boosting the growth of the global Cancer Pain Management market.
Moreover, rising incidences of cancer across the world and increasing healthcare spending are anticipated to propel the growth of the global cancer pain management market. The World Health Organization spells out the need to step up cancer services in low and middle-income countries. WHO warns that, if current trends continue, the world will see a 60% increase in cancer cases over the next two decades. The greatest increase i.e., an estimated 81% in new cases will occur in low- and middle-income countries, where survival rates are currently lowest.
Furthermore, increasing research and development activities rises the range of drugs, as more drugs could mean a rise in demand. This crucial fact is majorly contributing to the growth of the global cancer pain management market.
Covid-19 Impact on Cancer Pain Management Market:
In addition, the current Cancer Pain Management Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Pain Management Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Pain Management Market Segment Overview
According to treatment type, Opioids are the largest segment of the market. Opioids are considered to be the most effective way of pain management, while combined pain management therapies and medication are more effective. Additionally, other factors such as technological developments for better alternatives for pain management and favorable government initiatives and funding are significantly taking part in the development of the Cancer Pain Management market.
Moreover, tremendously rising cases of cancer induce healthcare providers to grow focus on their goals of treating cancer and pain management, which is possible to require cancer pain management methods that are specific, efficient, and sensitive. This key factor also fuelling the growth of the global Cancer Pain Management market.
Cancer Pain Management Market, By Treatment Type
· Lung Cancer
· Colorectal Cancer
· Breast Cancer
· Prostate Cancer
· Blood Cancer
· Others
Cancer Pain Management Market Regional Overview
In terms of region, North America commanded a major share of the Cancer Pain Management market. This is on account of the presence of leading players, high healthcare spending, and well-established healthcare infrastructure in this region. On the other hand, the market in Asia-Pacific is expected to witness significant growth during the forecast period. Factors such as development in the healthcare facilities and increasing healthcare funding by the governments of several countries like India, China, and Brazil are prilling the growth of the market. Beyond this, rising awareness about cancer and its pain management is further facilitating market development in this region.
Cancer Pain Management Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Pain Management Market, Key Players
· Abbott
· Boston Scientific Corporation
· Baxter
· Medtronic plc.
· Olympus
The global Cancer Pain Management market is expected to rise at a significant rate in the forecast period. Approximately 70.0% of cancer patients could suffer from chronic pain because of spinal cord injuries, 28.0% due to multiple sclerosis, and 8.0% due to stroke. In addition, 75.0% of the patients are projected to complain of a gradual rise in pain with the progression of the disease. Therefore, a growing number of patients experiencing such pain will be boosting the growth of the global Cancer Pain Management market.
Moreover, rising incidences of cancer across the world and increasing healthcare spending are anticipated to propel the growth of the global cancer pain management market. The World Health Organization spells out the need to step up cancer services in low and middle-income countries. WHO warns that, if current trends continue, the world will see a 60% increase in cancer cases over the next two decades. The greatest increase i.e., an estimated 81% in new cases will occur in low- and middle-income countries, where survival rates are currently lowest.
Furthermore, increasing research and development activities rises the range of drugs, as more drugs could mean a rise in demand. This crucial fact is majorly contributing to the growth of the global cancer pain management market.
Covid-19 Impact on Cancer Pain Management Market:
In addition, the current Cancer Pain Management Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Pain Management Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Pain Management Market Segment Overview
According to treatment type, Opioids are the largest segment of the market. Opioids are considered to be the most effective way of pain management, while combined pain management therapies and medication are more effective. Additionally, other factors such as technological developments for better alternatives for pain management and favorable government initiatives and funding are significantly taking part in the development of the Cancer Pain Management market.
Moreover, tremendously rising cases of cancer induce healthcare providers to grow focus on their goals of treating cancer and pain management, which is possible to require cancer pain management methods that are specific, efficient, and sensitive. This key factor also fuelling the growth of the global Cancer Pain Management market.
Cancer Pain Management Market, By Treatment Type
- Medications
- Opioids/Narcotics
- Morphine
- Fentanyl
- Others
- Non-Opioids
- Acetaminophen
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Nerve Blocks
- Opioids/Narcotics
- Devices or Systems
- Electrical Stimulation Devices
- Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- Neuromuscular Electrical Stimulation (NMES/EMS) Devices
- Others (Electrotherapy Devices, Combination Devices, etc.)
- Analgesic Infusion Pumps
- Intrathecal Infusion Pumps
- External Infusion Pumps
- Neurostimulation Devices
- Spinal Cord Stimulation (SCS) Devices
- Deep Brain Stimulation Devices
- Others
- Radiofrequency Ablation Devices
- Electrical Stimulation Devices
· Lung Cancer
· Colorectal Cancer
· Breast Cancer
· Prostate Cancer
· Blood Cancer
· Others
Cancer Pain Management Market Regional Overview
In terms of region, North America commanded a major share of the Cancer Pain Management market. This is on account of the presence of leading players, high healthcare spending, and well-established healthcare infrastructure in this region. On the other hand, the market in Asia-Pacific is expected to witness significant growth during the forecast period. Factors such as development in the healthcare facilities and increasing healthcare funding by the governments of several countries like India, China, and Brazil are prilling the growth of the market. Beyond this, rising awareness about cancer and its pain management is further facilitating market development in this region.
Cancer Pain Management Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Pain Management Market, Key Players
· Abbott
· Boston Scientific Corporation
· Baxter
· Medtronic plc.
· Olympus
Cancer Pain Management Market Study Global Market Analysis, Insights and Forecast, 2020-2027
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Cancer Pain Management Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Treatment Type
- 5.2.1. Medications
- 5.2.1.1. Opioids/Narcotics
- 5.2.1.1.1. Morphine
- 5.2.1.1.2. Fentanyl
- 5.2.1.1.3. Others
- 5.2.1.2. Non-Opioids
- 5.2.1.2.1. Acetaminophen
- 5.2.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.2.1.3. Nerve Blocks
- 5.2.1.1. Opioids/Narcotics
- 5.2.2. Devices or Systems
- 5.2.2.1. Electrical Stimulation Devices
- 5.2.2.1.1. Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- 5.2.2.1.2. Neuromuscular Electrical Stimulation (NMES/EMS) Devices
- 5.2.2.1.3. Others (Electrotherapy Devices, Combination Devices, etc.)
- 5.2.2.2. Analgesic Infusion Pumps
- 5.2.2.2.1. Intrathecal Infusion Pumps
- 5.2.2.2.2. External Infusion Pumps
- 5.2.2.3. Neurostimulation Devices
- 5.2.2.3.1. Spinal Cord Stimulation (SCS) Devices
- 5.2.2.3.2. Deep Brain Stimulation Devices
- 5.2.2.3.3. Others
- 5.2.2.4. Radiofrequency Ablation Devices
- 5.2.2.1. Electrical Stimulation Devices
- 5.3. Market Analysis, Insights and Forecast – By Disease Indication
- 5.3.1. Lung Cancer
- 5.3.2. Colorectal Cancer
- 5.3.3. Breast Cancer
- 5.3.4. Prostate Cancer
- 5.3.5. Blood Cancer
- 5.3.6. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
- 5.2.1. Medications
6. North America Cancer Pain Management Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Treatment Type
- 6.2.1. Medications
- 6.2.1.1. Opioids/Narcotics
- 6.2.1.1.1. Morphine
- 6.2.1.1.2. Fentanyl
- 6.2.1.1.3. Others
- 6.2.1.2. Non-Opioids
- 6.2.1.2.1. Acetaminophen
- 6.2.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- 6.2.1.3. Nerve Blocks
- 6.2.1.1. Opioids/Narcotics
- 6.2.2. Devices or Systems
- 6.2.2.1. Electrical Stimulation Devices
- 6.2.2.1.1. Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- 6.2.2.1.2. Neuromuscular Electrical Stimulation (NMES/EMS) Devices
- 6.2.2.1.3. Others (Electrotherapy Devices, Combination Devices, etc.)
- 6.2.2.2. Analgesic Infusion Pumps
- 6.2.2.2.1. Intrathecal Infusion Pumps
- 6.2.2.2.2. External Infusion Pumps
- 6.2.2.3. Neurostimulation Devices
- 6.2.2.3.1. Spinal Cord Stimulation (SCS) Devices
- 6.2.2.3.2. Deep Brain Stimulation Devices
- 6.2.2.3.3. Others
- 6.2.2.4. Radiofrequency Ablation Devices
- 6.2.2.1. Electrical Stimulation Devices
- 6.3. Market Analysis, Insights and Forecast – By Disease Indication
- 6.3.1. Lung Cancer
- 6.3.2. Colorectal Cancer
- 6.3.3. Breast Cancer
- 6.3.4. Prostate Cancer
- 6.3.5. Blood Cancer
- 6.3.6. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 6.2.1. Medications
7. Europe Cancer Pain Management Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Treatment Type
- 7.2.1. Medications
- 7.2.1.1. Opioids/Narcotics
- 7.2.1.1.1. Morphine
- 7.2.1.1.2. Fentanyl
- 7.2.1.1.3. Others
- 7.2.1.2. Non-Opioids
- 7.2.1.2.1. Acetaminophen
- 7.2.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- 7.2.1.3. Nerve Blocks
- 7.2.1.1. Opioids/Narcotics
- 7.2.2. Devices or Systems
- 7.2.2.1. Electrical Stimulation Devices
- 7.2.2.1.1. Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- 7.2.2.1.2. Neuromuscular Electrical Stimulation (NMES/EMS) Devices
- 7.2.2.1.3. Others (Electrotherapy Devices, Combination Devices, etc.)
- 7.2.2.2. Analgesic Infusion Pumps
- 7.2.2.2.1. Intrathecal Infusion Pumps
- 7.2.2.2.2. External Infusion Pumps
- 7.2.2.3. Neurostimulation Devices
- 7.2.2.3.1. Spinal Cord Stimulation (SCS) Devices
- 7.2.2.3.2. Deep Brain Stimulation Devices
- 7.2.2.3.3. Others
- 7.2.2.4. Radiofrequency Ablation Devices
- 7.2.2.1. Electrical Stimulation Devices
- 7.3. Market Analysis, Insights and Forecast – By Disease Indication
- 7.3.1. Lung Cancer
- 7.3.2. Colorectal Cancer
- 7.3.3. Breast Cancer
- 7.3.4. Prostate Cancer
- 7.3.5. Blood Cancer
- 7.3.6. Others
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
- 7.2.1. Medications
8. Asia Pacific Cancer Pain Management Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Treatment Type
- 8.2.1. Medications
- 8.2.1.1. Opioids/Narcotics
- 8.2.1.1.1. Morphine
- 8.2.1.1.2. Fentanyl
- 8.2.1.1.3. Others
- 8.2.1.2. Non-Opioids
- 8.2.1.2.1. Acetaminophen
- 8.2.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- 8.2.1.3. Nerve Blocks
- 8.2.1.1. Opioids/Narcotics
- 8.2.2. Devices or Systems
- 8.2.2.1. Electrical Stimulation Devices
- 8.2.2.1.1. Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- 8.2.2.1.2. Neuromuscular Electrical Stimulation (NMES/EMS) Devices
- 8.2.2.1.3. Others (Electrotherapy Devices, Combination Devices, etc.)
- 8.2.2.2. Analgesic Infusion Pumps
- 8.2.2.2.1. Intrathecal Infusion Pumps
- 8.2.2.2.2. External Infusion Pumps
- 8.2.2.3. Neurostimulation Devices
- 8.2.2.3.1. Spinal Cord Stimulation (SCS) Devices
- 8.2.2.3.2. Deep Brain Stimulation Devices
- 8.2.2.3.3. Others
- 8.2.2.4. Radiofrequency Ablation Devices
- 8.2.2.1. Electrical Stimulation Devices
- 8.3. Market Analysis, Insights and Forecast – By Disease Indication
- 8.3.1. Lung Cancer
- 8.3.2. Colorectal Cancer
- 8.3.3. Breast Cancer
- 8.3.4. Prostate Cancer
- 8.3.5. Blood Cancer
- 8.3.6. Others
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
- 8.2.1. Medications
9. Latin America, Middle East and Africa Cancer Pain Management Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Treatment Type
- 9.2.1. Medications
- 9.2.1.1. Opioids/Narcotics
- 9.2.1.1.1. Morphine
- 9.2.1.1.2. Fentanyl
- 9.2.1.1.3. Others
- 9.2.1.2. Non-Opioids
- 9.2.1.2.1. Acetaminophen
- 9.2.1.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- 9.2.1.3. Nerve Blocks
- 9.2.1.1. Opioids/Narcotics
- 9.2.2. Devices or Systems
- 9.2.2.1. Electrical Stimulation Devices
- 9.2.2.1.1. Transcutaneous Electrical Nerve Stimulation (TENS) Devices
- 9.2.2.1.2. Neuromuscular Electrical Stimulation (NMES/EMS) Devices
- 9.2.2.1.3. Others (Electrotherapy Devices, Combination Devices, etc.)
- 9.2.2.2. Analgesic Infusion Pumps
- 9.2.2.2.1. Intrathecal Infusion Pumps
- 9.2.2.2.2. External Infusion Pumps
- 9.2.2.3. Neurostimulation Devices
- 9.2.2.3.1. Spinal Cord Stimulation (SCS) Devices
- 9.2.2.3.2. Deep Brain Stimulation Devices
- 9.2.2.3.3. Others
- 9.2.2.4. Radiofrequency Ablation Devices
- 9.2.2.1. Electrical Stimulation Devices
- 9.3. Market Analysis, Insights and Forecast – By Disease Indication
- 9.3.1. Lung Cancer
- 9.3.2. Colorectal Cancer
- 9.3.3. Breast Cancer
- 9.3.4. Prostate Cancer
- 9.3.5. Blood Cancer
- 9.3.6. Others
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
- 9.2.1. Medications
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Abbott
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Boston Scientific Corporation
- 10.6. Baxter
- 10.7. Medtronic plc.
Research Process
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
